Schonfeld Strategic Advisors’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$515K Buy
+69,374
New +$730K ﹤0.01% 1373
2025
Q3
Sell
-128,280
Closed -$938K 2438
2025
Q2
$938K Buy
+128,280
New +$1.04M 0.01% 1328
2025
Q1
Sell
-16,280
Closed -$268K 2400
2024
Q4
$268K Sell
16,280
-54,330
-77% -$844K ﹤0.01% 1654
2024
Q3
$1.04M Buy
70,610
+13,170
+23% +$206K 0.01% 1147
2024
Q2
$797K Buy
+57,440
New +$814K 0.01% 1300
2024
Q1
Sell
-80,930
Closed -$1.31M 2285
2023
Q4
$1.31M Sell
80,930
-7,478
-8% -$122K 0.01% 944
2023
Q3
$1.09M Sell
88,408
-48,408
-35% -$720K 0.01% 994
2023
Q2
$2.2M Buy
+136,816
New +$2.25M 0.02% 721
2022
Q4
Sell
-67,100
Closed -$578K 2871
2022
Q3
$578K Buy
+67,100
New +$666K ﹤0.01% 1651
2018
Q4
Sell
-60,000
Closed -$921K 1184
2018
Q3
$921K Buy
+60,000
New +$829K 0.04% 443

Other funds holding NEO

Schonfeld Strategic Advisors's NEO Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in NeoGenomics (NEO) in Q1 2026: 69,374 shares worth $515K. The stake represents ﹤0.01% of the portfolio and ranks #1373 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in NEO as recently as Q2 2025.

Schonfeld Strategic Advisors first reported a position in NEO in Q3 2018 and has held it in 10 quarters since. The position peaked at $2.2M in Q2 2023. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

  • Schonfeld Strategic Advisors held 69,374 shares of NeoGenomics worth $515K as of Q1 2026.
  • NeoGenomics was a new Schonfeld Strategic Advisors position in Q1 2026.
  • NeoGenomics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1373 holding.
  • Schonfeld Strategic Advisors first reported a position in NeoGenomics in Q3 2018 and has held it in 10 quarters since.
  • Schonfeld Strategic Advisors's NeoGenomics position peaked at $2.2M in Q2 2023.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.